Answers are grounded in this paper and cite their sources.
Background and Objectives: Antiseizure medications are widely prescribed and approved for a number of therapeutic indications such as epilepsy, migraine prophylaxis, neuropathic pain and bipolar disorder. Since antiseizure drugs have narrow therapeutic index having multiple adverse drug reactions (ADRs), they tend to have significant safety concerns. The objectives of the study were to assess the pattern of adverse drug reactions to antiseizure drugs in adult patients; to assess the causality, severity and preventability of ADRs to antiseizure drugs. Methods: A written informed consent was taken from participants who fulfilled inclusion criteria and willing to participate. ADRs were detected by interviewing participants and the consulting physician. Causality assessment of the ADRs was done using WHO-UMC scale and Naranjo's scale. Severity and preventability of ADRs were assessed using Hartwig and Siegel scale and modified Schumock and Thornton scale respectively. Results: Out of 131 participants who were included in this study, 40.5% had ADRs. Levetiracetam was the most commonly prescribed drug. Majority of the ADRs belonged to possible category according to WHO-UMC scale (63.1%) and Naranjo's scale (69.2%). According to Hartwig's and Siegel's severity scale 49.2% of them were mild and as per modified Schumock and Thornton preventability scale, 97% of them were not preventable. Conclusion: Neurological and CNS manifestations dominated the ADR spectrum, accounting for 66.2% of all recorded reactions. The overall ADR prevalence of 40.5% highlights the need for continuous monitoring in patients receiving long-term antiseizure therapy.
No takes yet. Share an insight, caveat, or question.
SHETTY et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: